Post-earnings recap
Reported
Wed, Nov 3, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Protagonist Therapeutics reported a wider-than-expected loss per share, which may raise concerns among investors. However, the stock still reacted positively, gaining 2.11%, likely due to management's focus on clinical progress and long-term strategy. Investors may view this as a sign of resilience despite the earnings miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.70 | N/A | -4.17% |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism about future developments. They noted that while the EPS was below expectations, the company is focused on its long-term goals.
Management highlighted ongoing progress in clinical trials.
They emphasized commitment to advancing their pipeline despite current losses.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—